3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Interventions
Nivolumab
37
pembrolizumab
30
cabozantinib
27
Specimen Handling
25
Magnetic Resonance Spectroscopy
22
Ipilimumab
20
lenvatinib
16
Axitinib
15
belzutifan
13
CTLA-4 Antigen
10
Sunitinib
9
Biopsy
9
Radiosurgery
8
atezolizumab
7
Immunoglobulin G
5
toripalimab
4
fludarabine
4
avelumab
4
aldesleukin
4
Everolimus
4
Disulfides
4
Cyclophosphamide
4
zimberelimab
3
tivozanib
3
spartalizumab
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Blood Component Removal
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled